OSE narrows pipeline focus amid Boehringer MASH collaboration retreat [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
French biotech OSE Therapeutics has shifted focus to its later-stage clinical assets as it looks to prioritise near-term value creation. OSE's pipeline rejig comes as Boehringer Ingelheim relinquishes its stake in the company's clinical-stage metabolic dysfunction-associated steatohepatitis (MASH) therapy, BI 770371, which failed to show efficacy in an exploratory Phase II study (NCT06675929). Boehringer originally signed a deal expansion with OSE to look into BI 770371's potential in MASH back in May 2024. According to OSE, this agreement does not impact the oncology-focused agreements the biotech holds with Boehringer. In line with its three-year strategic plan, OSE is pausing the development of ChemR23-targeted inflammatory disease candidate, OSE-230 – which the company began co-developing with AbbVie in February 2024 after the latter purchased the global rights to the drug for $48m. While AbbVie originally planned to take the reins on this asset's preclinical and Phase I de
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- ???????????????????? : ????????:2035????1856?9000??????????CAGR17.9%???????????????????? [CNET News]CNET News
- AbbVie: The Only Big Pharma Stock I'd Consider a Buy-and-Never-Sell [Yahoo! Finance]Yahoo! Finance
- ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTSPR Newswire
- AbbVie to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- AbbVie to Present at the Leerink Partners Global Healthcare ConferencePR Newswire
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 3/4/26 - Form 8-K
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- ABBV's page on the SEC website